


### Remarks

The claims have been amended to define a method and formulation for using glycosaminoglycan-degrading enzymes to modulate the interactions involved in endothelial cell proliferation by treating, removing or degrading glycosaminoglycans from proteoglycans. Support for these amendments is found in the specification at least on page 5, lines 7-10; page 6, lines 5-14; page 4, lines 11-14 and page 11, lines 2-4.

Claim 18 has been amended to define agents that can be coadministered with the enzyme including antibiotics, cytokines and antiinflammatories. Support for this amendment is found on page 9, lines 26-30 of the specification.

Examination of claims 1-18 is respectfully solicited.

Respectfully submitted,



Zhaoyang Li  
Reg. No. 46,872

Date: July 18, 2003

HOLLAND & KNIGHT LLP  
One Atlantic Center, Suite 2000  
1201 West Peachtree Street  
Atlanta, Georgia 30309-3400  
(404) 817-8473  
(404) 817-8588 (Fax)

ATL1 #585862 v2